Related references
Note: Only part of the references are listed.Neu-horizons: neuroprotection and therapeutic use of riluzole for the prevention of oxaliplatin-induced neuropathy-a randomised controlled trial
Terry Trinh et al.
SUPPORTIVE CARE IN CANCER (2021)
Riluzole: A neuroprotective drug with potential as a novel anti-cancer agent (Review)
Angelina Blyufer et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2021)
Riluzole: Anti-invasive effects on rat prostate cancer cells under normoxic and hypoxic conditions
Nahit Rizaner et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2020)
Cystine/glutamate antiporter xCT (SLC7A11) facilitates oncogenic RAS transformation by preserving intracellular redox balance
Jonathan K. M. Lim et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
HERG1 promotes esophageal squamous cell carcinoma growth and metastasis through TXNDC5 by activating the PI3K/AKT pathway
Hongqiang Wang et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
A polyprodrug-based nanoplatform for cisplatin prodrug delivery and combination cancer therapy
Chunhao Lin et al.
CHEMICAL COMMUNICATIONS (2019)
The cisplatin-based Pt(IV)-diclorofibrato multi-action anticancer prodrug exhibits excellent performances also under hypoxic conditions
Elisabetta Gabano et al.
DALTON TRANSACTIONS (2018)
ION CHANNELS IN CANCER: ARE CANCER HALLMARKS ONCOCHANNELOPATHIES?
Natalia Prevarskaya et al.
PHYSIOLOGICAL REVIEWS (2018)
Emerging molecular mechanisms in chemotherapy: Ca2+ signaling at the mitochondria-associated endoplasmic reticulum membranes
Martijn Kerkhofs et al.
CELL DEATH & DISEASE (2018)
Targeting the TREK-1 potassium channel via riluzole to eliminate the neuropathic and depressive-like effects of oxaliplatin
Laura Poupon et al.
NEUROPHARMACOLOGY (2018)
Participation of xCT in melanoma cell proliferation in vitro and tumorigenesis in vivo
Seung-Shick Shin et al.
ONCOGENESIS (2018)
The combined activation of K(Ca)3.1 and inhibition of K(v)11.1/hERG1 currents contribute to overcome Cisplatin resistance in colorectal cancer cells
Serena Pillozzi et al.
BRITISH JOURNAL OF CANCER (2018)
The role of hERG1 ion channels in epithelial-mesenchymal transition and the capacity of riluzole to reduce cisplatin resistance in colorectal cancer cells
Angelo Fortunato
CELLULAR ONCOLOGY (2017)
Riluzole synergizes with paclitaxel to inhibit cell growth and induce apoptosis in triple-negative breast cancer
Cecilia L. Speyer et al.
BREAST CANCER RESEARCH AND TREATMENT (2017)
Biotin-tagged platinum(IV) complexes as targeted cytostatic agents against breast cancer cells
Nafees Muhammad et al.
CHEMICAL COMMUNICATIONS (2017)
Silencing of hERG1 Gene Inhibits Proliferation and Invasion, and Induces Apoptosis in Human Osteosarcoma Cells by Targeting the NF-κB Pathway
Wenrong Zeng et al.
Journal of Cancer (2016)
hERG1 channels drive tumour malignancy and may serve as prognostic factor in pancreatic ductal adenocarcinoma
E. Lastraioli et al.
BRITISH JOURNAL OF CANCER (2015)
Cellular trafficking, accumulation and DNA platination of a series of cisplatin-based dicarboxylato Pt(IV) prodrugs
Mauro Ravera et al.
JOURNAL OF INORGANIC BIOCHEMISTRY (2015)
A Pt(IV) Pro-drug Preferentially Targets Indoleamine-2,3-dioxygenase, Providing Enhanced Ovarian Cancer Immuno-Chemotherapy
Samuel G. Awuah et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2015)
Recent Advances in Platinum (IV) Complex-Based Delivery Systems to Improve Platinum (II) Anticancer Therapy
Xiaopeng Han et al.
MEDICINAL RESEARCH REVIEWS (2015)
Stimulation of hERG1 channel activity promotes a calcium-dependent degradation of cyclin E2, but not cyclin E1, in breast cancer cells
Mathew Perez-Neut et al.
ONCOTARGET (2015)
hERG1 Channels Regulate VEGF-A Secretion in Human Gastric Cancer: Clinicopathological Correlations and Therapeutical Implications
Olivia Crociani et al.
CLINICAL CANCER RESEARCH (2014)
Understanding Intrinsically Irreversible, Non-Nernstian, Two-Electron Redox Processes: A Combined Experimental and Computational Study of the Electrochemical Activation of Platinum(IV) Antitumor Prodrugs
Meghan C. McCormick et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2014)
Targeted Theranostic Platinum(IV) Prodrug with a Built-In Aggregation-Induced Emission Light-Up Apoptosis Sensor for Noninvasive Early Evaluation of Its Therapeutic Responses in Situ
Youyong Yuan et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2014)
What do we know about the reduction of Pt(IV) pro-drugs?
Ezequiel Wexselblatt et al.
JOURNAL OF INORGANIC BIOCHEMISTRY (2012)
Capsaicin represses transcriptional activity of β-catenin in human colorectal cancer cells
Seong-Ho Lee et al.
JOURNAL OF NUTRITIONAL BIOCHEMISTRY (2012)
Disruption of xCT inhibits cell growth via the ROS/autophagy pathway in hepatocellular carcinoma
Weijie Guo et al.
CANCER LETTERS (2011)
Antiproliferative Pt(IV) complexes: synthesis, biological activity, and quantitative structure-activity relationship modeling
Paola Gramatica et al.
JOURNAL OF BIOLOGICAL INORGANIC CHEMISTRY (2010)
Oxaliplatin-Induced Chronic Peripheral Neurotoxicity: A Prospective Analysis in Patients with Colorectal Cancer
Kyung Kee Baek et al.
CANCER RESEARCH AND TREATMENT (2010)
E-cadherin, β-catenin, and ZEB1 in malignant progression of cancer
Otto Schmalhofer et al.
CANCER AND METASTASIS REVIEWS (2009)
Targeting Ion Channels in Cancer: A Novel Frontier in Antineoplastic Therapy
A. Arcangeli et al.
CURRENT MEDICINAL CHEMISTRY (2009)
Naphtho[1,2-d]thiazol-2-ylamine (SKA-31), a New Activator of KCa2 and KCa3.1 Potassium Channels, Potentiates the Endothelium-Derived Hyperpolarizing Factor Response and Lowers Blood Pressure
Ananthakrishnan Sankaranarayanan et al.
MOLECULAR PHARMACOLOGY (2009)
Disruption of xCT inhibits cancer cell metastasis via the caveolin-1/β-catenin pathway
R-S Chen et al.
ONCOGENE (2009)
The epithelial-mesenchymal transition generates cells with properties of stem cells
Sendurai A. Mani et al.
CELL (2008)
Cisplatin nephrotoxicity: Mechanisms and renoprotective strategies
N. Pabla et al.
KIDNEY INTERNATIONAL (2008)
Basis for design and development of Platinum(IV) anticancer complexes
Matthew D. Hall et al.
JOURNAL OF MEDICINAL CHEMISTRY (2007)
The structural and functional units of heteromeric amino acid transporters -: The heavy subunit rBAT dictates oligomerization of the heteromeric amino acid transporters
Esperanza Fernandez et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Future opportunities in preventing cisplatin induced ototoxicity
J. H. van den Berg et al.
CANCER TREATMENT REVIEWS (2006)
Glutathione homeostasis and redox-regulation by sulfhydryl groups
AJ Meyer et al.
PHOTOSYNTHESIS RESEARCH (2005)
Recognition and processing of cisplatin- and oxaliplatin-DNA adducts
SG Chaney et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2005)
Update of the preclinical situation of anticancer platinum complexes: Novel design strategies and innovative analytical approaches
M Galanski et al.
CURRENT MEDICINAL CHEMISTRY (2005)
Expression of the activity of cystine/glutamate exchange transporter, system xc-, by xCT and rBAT
HY Wang et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2003)
Reciprocal expressions of cyclin E and cyclin D1 in hepatocellular carcinoma
YJ Jung et al.
CANCER LETTERS (2001)
E-cadherin-catenin cell-cell adhesion complex and human cancer
BPL Wijnhoven et al.
BRITISH JOURNAL OF SURGERY (2000)
Share Paper
